Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: (2R,4S)-1-TERT-BUTYL 2-METHYL 4-HYDROXYPYRROLIDINE-1,2-DICARBOXYLATE
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang
Email: enquiry@dycnchem.com

135042-17-0

135042-17-0 structure

Name: Boc-trans-D-Hyp-OMe
Chemical Name: (2R,4S)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate
CAS Number: 135042-17-0
Molecular Formula: C₁₁H₁₉NO₅
Molecular Weight: 245.272
Catalog: Biochemical Amino acids and their derivatives Proline derivatives
Create Date: 2019-01-09 12:50:43
Modify Date: 2025-08-22 18:16:12
Boc-trans-D-Hyp-OMe is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-trans-D-Hyp-OMe is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2].

Name	(2R,4S)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate
Synonyms	1-O-tert-butyl 2-O-methyl (2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxylate (4S)-4-Hydroxy-2-methyl-1-{[(2-methyl-2-propanyl)oxy]carbonyl}-D-proline 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-2-methyl-, 1-(1,1-dimethylethyl) ester, (2R,4S)-

Description	Boc-trans-D-Hyp-OMe is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Boc-trans-D-Hyp-OMe is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Antibody-drug Conjugate >> ADC Linker Signaling Pathways >> PROTAC >> PROTAC Linker
Target	Non-cleavable
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
References	[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337. [2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

Hazard Codes	Xi